BTIG analyst Ryan Zimmerman maintained a Hold rating on Integra Lifesciences (IART – Research Report) today. The company’s shares closed today ...

Analyst Craig Bijou of Bank of America Securities reiterated a Sell rating on Integra Lifesciences (IART – Research Report), with a price ...

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest ...

Integra Lifesciences recently received an FDA warning letter pertaining to quality systems issues at several facilities.

Integra LifeSciences Holdings said a subsidiary received a warning letter from the Food and Drug Administration over issues identified during inspections at three company facilities.

Clearly, options traders are pricing in a big move for Integra LifeSciences shares, but what is the fundamental picture for the company? Currently, Integra LifeSciences is a Zacks Rank #2 (Buy ...

One company to watch right now is Integra LifeSciences (IART). IART is currently sporting a Zacks Rank of #2 (Buy) and an A for Value. Value investors also frequently use the P/S ratio.

Integra LifeSciences Holdings Corp (NASDAQ:IART), a medical device company with a market capitalization of $1.79 billion, disclosed Monday that it received a warning letter from the U.S. Food and ...